ClinicalTrials.gg
RecruitingNCT07544654Updated Nov 10, 2026

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

A Phase 3 interventional study of Obrixtamig and Carboplatin in Extrapulmonary Neuroendocrine Cancer (epNEC), sponsored by Boehringer Ingelheim. Recruiting at 170 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 10, 2026Site recruiting status changedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3).

Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein.

During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works.

02

Conditions studied

  • Extrapulmonary Neuroendocrine Cancer (epNEC)
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with poorly differentiated unresectable locally advanced or extrapulmonary neuroendocrine carcinoma (epNEC) with Ki-67 >20% or mitotic rate mitotic rate with number of mitoses >20 per 2 mm2, regardless of primary site (including site of unknown origin)
  2. Patients with tumours with mixed histologies are eligible only if neuroendocrine carcinoma component is predominant and represents more than 70% of the overall tumour tissue
  3. No prior systemic treatment for unresectable locally advanced or metastatic epNEC (except for the completed one cycle of standard platinum + etoposide). Prior peri-operative chemotherapy or -radiation for curative intention is allowed if at least 6 months have elapsed between completion of this therapy and diagnosis of unresectable locally advanced or metastatic disease
  4. Patients who have finished one cycle of standard platinum + etoposide regimen as treatment (Cycle 0: etoposide with carboplatin or cisplatin, administered at a minimum dose of cisplatin 75 mg/m2 or carboplatin area under the curve (AUC) 5 and etoposide 80 mg/m2) prior to randomisation
  5. Patients must comply with criteria for receiving further chemotherapy treatment as first-line standard of care (SoC) treatment within 28 days after the start of the initial chemotherapy (Cycle 0)
  6. Adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status. Tumours must be positive (as defined in the diagnostic study protocol) for DLL3 expression status assessed by VENTANA DLL3 (SP347) RxDx Assay
  7. (ECOG) score of 0 or 1
  8. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the form (ICF) Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Presence of and/or carcinomatous meningitis
  2. Patients with diagnosis of Merkel cell carcinoma or medullary thyroid carcinoma
  3. Patients with neuroendocrine prostate cancer
  4. Patients with well-differentiated neuroendocrine tumours of any grade according to the world health organization (WHO) classification, 5th edition
  5. Patients with a history of well differentiated Neuroendocrine tumour (NET) tumour that transformed into poorly differentiated Neuroendocrine carcinoma (NEC)
  6. Previous treatment with obrixtamig or other DLL3-targeting therapies (e.g. T-cell engager (TcEs), cell therapies, antibody-drug conjugates, or radiopharmaceuticals)
  7. Previous treatment with or programmed death ligand 1 (PD-L1) therapies during the one cycle of standard platinum + etoposide chemotherapy (Cycle 0)
  8. Toxicity from previous treatments that has not resolved to ≤ (CTCAE) Grade 1 or grade prior to Cycle 0. Participants with alopecia any grade, CTCAE ≤Grade 2 asthenia/fatigue, amenorrhea/menstrual disorders any grade, CTCAE ≤Grade 2 peripheral neuropathy, and/or CTCAE ≤Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks, per Investigator judgement may be eligible Further exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Obrixtamig + carboplatin + etoposide

    Treatment arm

    Drug: Obrixtamig · Drug: Carboplatin · Drug: Etoposide · Device: Ventana DLL3 RxDx assay

  • Active comparator
    Carboplatin + etoposide

    Control arm

    Drug: Carboplatin · Drug: Etoposide · Device: Ventana DLL3 RxDx assay

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    defined as the time from randomisation until death from any cause

    Time frame: Up to 38 months

Secondary outcomes

  1. Progression-free survival (PFS)

    defined as the time from randomisation until the earliest date of disease progression according to RECIST 1.1 based on investigator assessments or death from any cause, whichever occurs first

    Time frame: Up to 38 months

  2. Change from baseline to Week 19 in the physical functioning domain of the EORTC QLQ-C30

    European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) includes 1 global health status/QoL scale, 5 functional scales, 3 symptoms scales and 6 single items to assess dyspnea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties. Each score 0-100. Global health status higher = better, functional scale higher = better, symptom scale higher = worse

    Time frame: At baseline, up to week 19

  3. Objective response (OR)

    defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 (based on investigator assessments) from randomisation until the earliest date of disease progression, death, last evaluable tumour assessment before the start of next line of anti-cancer treatment, loss to follow-up, or withdrawal of consent

    Time frame: Up to 38 months

  4. Duration of response (DoR)

    defined as the time from the first documented OR according to RECIST 1.1 until the earliest date of disease progression or death among patients with objective response based on investigator assessments

    Time frame: Up to 38 months

  5. Disease control (DC)

    defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST 1.1 based on investigator assessments from randomisation until the earliest of disease progression, death or last evaluable tumour assessment before start of next line of anti-cancer treatment, loss to follow-up or withdrawal of consent

    Time frame: Up to 38 months

  6. Occurrence of treatment-emergent Grade 3 or greater Cytokine release syndrome (CRS)

    Time frame: Up to 38 months

  7. Occurrence of treatment-emergent Grade 3 or greater Immune cell associated neurotoxicity syndrome (ICANS)

    Time frame: Up to 38 months

  8. Occurrence of treatment-emergent adverse events (AEs) leading to permanent discontinuation of trial medication during the on-treatment period

    Time frame: Up to 38 months

  9. Occurrence of treatment-emergent AEs leading to dose modification of trial medication (i.e. dose interruption, dose delay, dose reduction)

    Time frame: Up to 38 months

07

Study locations

109 of 170 sites recruiting

Showing the first 100 of 170 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Dec 2029, 41 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2031 → Dec 2029, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 22, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Dec 13, 2029
CompletionEst.
Dec 13, 2029was Mar 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 6 sites removed. 58 sites changed recruiting status (58 now recruiting)
Show 58 sites
  • Sunnybrook Health Sciences Centre · Toronto, CanadaNot yet recruiting→Recruiting
  • The First Affiliated Hospital,Sun Yat-sen University · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Harbin Medical University Cancer Hospital · Harbin, ChinaNot yet recruiting→Recruiting
  • HOP François Mitterrand · Dijon, FranceNot yet recruiting→Recruiting
  • Universitätsklinikum Heidelberg · Heidelberg, GermanyNot yet recruiting→Recruiting
  • Kanazawa University Hospital · Ishikawa, Kanazawa, JapanNot yet recruiting→Recruiting
  • Kyoto University Hospital · Kyoto, Kyoto, JapanNot yet recruiting→Recruiting
  • Helse Stavanger, Stavanger Universitetssykehus · Stavanger, NorwayNot yet recruiting→Recruiting
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, SpainNot yet recruiting→Recruiting
  • Royal North Shore Hospital · St Leonards, AustraliaNot yet recruiting→Recruiting
  • ICESP - Instituto do Cancer do Estado de Sao Paulo · São Paulo, BrazilNot yet recruiting→Recruiting
  • Aarhus University Hospital · Aarhus N, DenmarkNot yet recruiting→Recruiting
  • Helsinki University Hospital · Helsinki, FinlandNot yet recruiting→Recruiting
  • KYS Sädesairaala · Kuopio, FinlandNot yet recruiting→Recruiting
  • HOP Haut-Lévêque · Pessac, FranceNot yet recruiting→Recruiting
  • DRK Kliniken Berlin Köpenick · Berlin, GermanyNot yet recruiting→Recruiting
  • Asklepios Klinik St Georg · Hamburg, GermanyNot yet recruiting→Recruiting
  • Universitätsklinikum Tübingen · Tübingen, GermanyNot yet recruiting→Recruiting
  • Fondazione Policlinico Universitario Campus Bio-medico · Roma, ItalyNot yet recruiting→Recruiting
  • Okayama University Hospital · Okayama, Okayama, JapanNot yet recruiting→Recruiting
  • Haukeland Universitetssykehus · Bergen, NorwayNot yet recruiting→Recruiting
  • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Ramon Y Cajal · Madrid, SpainNot yet recruiting→Recruiting
  • Hospital Universitario 12 de Octubre · Madrid, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Marqués de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
  • Skånes universitetssjukhus · Lund, SwedenNot yet recruiting→Recruiting
  • Uppsala University Hospital · Uppsala, SwedenNot yet recruiting→Recruiting
  • Western General Hospital · Edinburgh, United KingdomNot yet recruiting→Recruiting
  • Instituto D'Or de Pesquisa E Ensino - Pe · Recife, BrazilNot yet recruiting→Recruiting
  • Instituto Oncologico FALP · Providencia, ChileNot yet recruiting→Recruiting
  • …and 28 more on the registry record
Show 9 added (3 Spain, 2 Canada, 2 France, 1 United Kingdom, 1 Argentina)
  • Hospital Universitario de Navarra · Pamplona, Spain
  • Arthur J. E. Child Comprehensive Cancer Centre · Calgary, Canada
  • Hopital Beaujon · Clichy, France
  • HOP Haut-Leveque · Pessac, France
  • Hospital Duran i Reynals · L'Hospitalet Del Llobregat, Spain
  • The Christie · Manchester, United Kingdom
  • Instituto Medico Especializado Alexander Fleming · Ciudad Autónoma de Bs As, Argentina
  • The Ottawa Hospital · Ottawa, Canada
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 6 removed
  • Complejo Hospitalario de Navarra · Pamplona, Spain
  • Azienda Universitaria Ospedaliera Consorziale Policlinico Bari · Bari, Italy
  • Hôpital Beaujon · Clichy, France
  • HOP Haut-Lévêque · Pessac, France
  • The Christie Hospital · Manchester, United Kingdom
  • Hospital Virgen del Rocio · Seville, Spain
across 4 updates, Sep 29, 2026 – Nov 10, 2026
Study completion
Mar 11, 2031→Dec 13, 2029
Oct 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Masaryk Memorial Cancer Institute · Brno, CzechiaContact •••0048→•••2046Contact s•••@bitrialsupport.com→c•••@bitrialsupport.com
  • University Hospital Hradec Kralove (FNHK) · Hradec Králové, CzechiaContact •••0048→•••2046Contact s•••@bitrialsupport.com→c•••@bitrialsupport.com
  • Instituto Jaliciense de Cancerología · Zapopan, MexicoContact removed m•••@bitrialsupport.com · •••3749
across 2 updates, Oct 28, 2026 – Nov 10, 2026
Show all 4 updates
  1. Nov 10, 2026
    3 sites added, 1 site removed. 21 sites changed recruiting status (21 now recruiting)
    Show 21 sites
    • A.C. Camargo · São Paulo, BrazilNot yet recruiting→Recruiting
    • Bradford Hill- Centro de Investigacion Clinica · Recoleta, ChileNot yet recruiting→Recruiting
    • Clinica Alemana de Santiago S.A. · Santiago, ChileNot yet recruiting→Recruiting
    • Xiangya Hospital, Central South University · Changsha, ChinaNot yet recruiting→Recruiting
    • Fujian Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
    • Tampere University Hospital · Tampere, FinlandNot yet recruiting→Recruiting
    • Turku University Hospital / TYKS · Turku, FinlandNot yet recruiting→Recruiting
    • Hôpital Edouard Herriot · Lyon, FranceNot yet recruiting→Recruiting
    • INS Paoli-Calmettes · Marseille, FranceNot yet recruiting→Recruiting
    • CTR Eugène Marquis · Rennes, FranceNot yet recruiting→Recruiting
    • Technische Universität Dresden · Dresden, GermanyNot yet recruiting→Recruiting
    • Universitätsklinikum Erlangen · Erlangen, GermanyNot yet recruiting→Recruiting
    • A. O. Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
    • Fondazione IRCCS Istituto Nazionale dei Tumori · Milan, ItalyNot yet recruiting→Recruiting
    • Istituto Europeo di Oncologia · Milan, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone · Palermo, ItalyNot yet recruiting→Recruiting
    • Centro Ricerche Cliniche di Verona S.r.l. · Verona, ItalyNot yet recruiting→Recruiting
    • St. Olavs Hospital, Universitetssykehuset i Trondheim · Trondheim, NorwayNot yet recruiting→Recruiting
    • Hospital CUF Porto · Porto, PortugalNot yet recruiting→Recruiting
    • Hospital Clinico De Valencia (INCLIVA) · Valencia, SpainNot yet recruiting→Recruiting
    • Addenbrooke's Hospital · Cambridge, United KingdomNot yet recruiting→Recruiting
    Show 3 added (1 Argentina, 1 Canada, 1 Spain)
    • Instituto Medico Especializado Alexander Fleming · Ciudad Autónoma de Bs As, Argentina
    • The Ottawa Hospital · Ottawa, Canada
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 1 removed
    • Hospital Virgen del Rocio · Seville, Spain
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Masaryk Memorial Cancer Institute · Brno, CzechiaContact •••0048→•••2046Contact s•••@bitrialsupport.com→c•••@bitrialsupport.com
    • University Hospital Hradec Kralove (FNHK) · Hradec Králové, CzechiaContact •••0048→•••2046Contact s•••@bitrialsupport.com→c•••@bitrialsupport.com
    • Instituto Jaliciense de Cancerología · Zapopan, MexicoContact removed m•••@bitrialsupport.com · •••3749
    + 1 other change: verification date
  2. Oct 28, 2026
    5 sites added, 3 sites removed. 9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Instituto D'Or de Pesquisa E Ensino - Pe · Recife, BrazilNot yet recruiting→Recruiting
    • Instituto Oncologico FALP · Providencia, ChileNot yet recruiting→Recruiting
    • Masaryk Memorial Cancer Institute · Brno, CzechiaNot yet recruiting→Recruiting
    • Istituto Nazionale IRCCS Tumori Fondazione Pascale · Naples, ItalyNot yet recruiting→Recruiting
    • Aichi Cancer Center Hospital · Aichi, Nagoya, JapanNot yet recruiting→Recruiting
    • Erasmus Medisch Centrum · Rotterdam, NetherlandsNot yet recruiting→Recruiting
    • Oslo Universitetssykehus HF, Radiumhospitalet · Oslo, NorwayNot yet recruiting→Recruiting
    • Hospital Regional Universitario de Malaga · Málaga, SpainNot yet recruiting→Recruiting
    • Hospital Virgen del Rocio · Seville, SpainNot yet recruiting→Recruiting
    Show 5 added (2 France, 1 Canada, 1 Spain, 1 United Kingdom)
    • Arthur J. E. Child Comprehensive Cancer Centre · Calgary, Canada
    • Hopital Beaujon · Clichy, France
    • HOP Haut-Leveque · Pessac, France
    • Hospital Duran i Reynals · L'Hospitalet Del Llobregat, Spain
    • The Christie · Manchester, United Kingdom
    Show 3 removed
    • Hôpital Beaujon · Clichy, France
    • HOP Haut-Lévêque · Pessac, France
    • The Christie Hospital · Manchester, United Kingdom
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Masaryk Memorial Cancer Institute · Brno, CzechiaContact •••2046→•••0048Contact c•••@bitrialsupport.com→s•••@bitrialsupport.com
    • University Hospital Hradec Kralove (FNHK) · Hradec Králové, CzechiaContact •••2046→•••0048Contact c•••@bitrialsupport.com→s•••@bitrialsupport.com
  3. Oct 13, 2026
    1 site removed. 19 sites changed recruiting status (19 now recruiting)
    Show 19 sites
    • Royal North Shore Hospital · St Leonards, AustraliaNot yet recruiting→Recruiting
    • ICESP - Instituto do Cancer do Estado de Sao Paulo · São Paulo, BrazilNot yet recruiting→Recruiting
    • Aarhus University Hospital · Aarhus N, DenmarkNot yet recruiting→Recruiting
    • Helsinki University Hospital · Helsinki, FinlandNot yet recruiting→Recruiting
    • KYS Sädesairaala · Kuopio, FinlandNot yet recruiting→Recruiting
    • HOP Haut-Lévêque · Pessac, FranceNot yet recruiting→Recruiting
    • DRK Kliniken Berlin Köpenick · Berlin, GermanyNot yet recruiting→Recruiting
    • Asklepios Klinik St Georg · Hamburg, GermanyNot yet recruiting→Recruiting
    • Universitätsklinikum Tübingen · Tübingen, GermanyNot yet recruiting→Recruiting
    • Fondazione Policlinico Universitario Campus Bio-medico · Roma, ItalyNot yet recruiting→Recruiting
    • Okayama University Hospital · Okayama, Okayama, JapanNot yet recruiting→Recruiting
    • Haukeland Universitetssykehus · Bergen, NorwayNot yet recruiting→Recruiting
    • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Ramon Y Cajal · Madrid, SpainNot yet recruiting→Recruiting
    • Hospital Universitario 12 de Octubre · Madrid, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Marqués de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
    • Skånes universitetssjukhus · Lund, SwedenNot yet recruiting→Recruiting
    • Uppsala University Hospital · Uppsala, SwedenNot yet recruiting→Recruiting
    • Western General Hospital · Edinburgh, United KingdomNot yet recruiting→Recruiting
    Show 1 removed
    • Azienda Universitaria Ospedaliera Consorziale Policlinico Bari · Bari, Italy
    Study completion Mar 11, 2031→Dec 13, 2029
    + 1 other change: verification date
  4. Sep 29, 2026
    1 site added, 1 site removed. 9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Sunnybrook Health Sciences Centre · Toronto, CanadaNot yet recruiting→Recruiting
    • The First Affiliated Hospital,Sun Yat-sen University · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Harbin Medical University Cancer Hospital · Harbin, ChinaNot yet recruiting→Recruiting
    • HOP François Mitterrand · Dijon, FranceNot yet recruiting→Recruiting
    • Universitätsklinikum Heidelberg · Heidelberg, GermanyNot yet recruiting→Recruiting
    • Kanazawa University Hospital · Ishikawa, Kanazawa, JapanNot yet recruiting→Recruiting
    • Kyoto University Hospital · Kyoto, Kyoto, JapanNot yet recruiting→Recruiting
    • Helse Stavanger, Stavanger Universitetssykehus · Stavanger, NorwayNot yet recruiting→Recruiting
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, SpainNot yet recruiting→Recruiting
    Show site
    • Hospital Universitario de Navarra · Pamplona, Spain
    Show 1 removed
    • Complejo Hospitalario de Navarra · Pamplona, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07544654
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Jul 10, 2026
Primary completion
Dec 13, 2029 (estimated)
Completion
Dec 13, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-012

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obrixtamig

Start the discussion